Special Issue "Advances in Amyloidosis: A Theme Issue in Honor of Prof. Dr. Giampaolo Merlini"
Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 40069
Interests: amyloidosis; monoclonal gammopathies of clinical significance; biomarkers
Interests: local and systemic amyloidosis; genetic of plasma cell dyscrasias; monoclonal gammopathies of clinical significance; auto and allo transplantation
Interests: myeloma; AL amyloidosis; monoclonal gammopathy of clinical significance; POEMS; transplantation
Special Issues, Collections and Topics in MDPI journals
Special Issue in Hemato: Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton
This Theme Issue aims to honor Prof. Giampaolo Merlini’s outstanding scientific and clinical achievements in the field of systemic amyloidosis. Prof. Merlini was introduced to the concept of “sick molecules and diseases” and to the then neglected and enigmatic condition of amyloidosis by his two mentors, Jan Waldenström and Elliott Osserman at the brink of his career. Since then, he has been devoting his life to elucidating the mechanism of this disease and translating his observations in better care for patients. Patients, in turn, are the constant source of inspiration for his research. Prof. Merlini demonstrated that amyloidogenic light chain exert a direct organ toxicity, discovered the first small molecule, iodo-deoxy-doxorubicin, which could interfere with the amyloidogenic process, set up innovative methods for the diagnosis of amyloidosis, introduced biomarkers in the staging and monitoring of this disease, and contributed to the development of most of the currently available therapeutic regimens. In the last forty years, our understanding of the mechanisms of amyloidosis has advanced greatly, providing novel therapeutic targets and reliable tools for diagnosis. In addition, prognostic stratification and monitoring of the disease became available, and we can now choose between an increasing number of effective therapeutic agents. Thanks to these developments, we are witnessing a constant improvement of the outcome of patients with amyloidosis.
This Special Issue will cover a diverse range of topics, from the classification and differential diagnosis of the various types of amyloidosis to the pathogenesis of clonal and organ disease in light chain amyloidosis. The placing of old and novel therapeutic strategies according to patients’ risk level will be discussed, as well as established and promising tools for disease monitoring.
Prof. Dr. Giovanni Palladini
Prof. Dr. Stefan Schönland
Dr. Laurent Garderet
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Biology of amyloid plasma cell clone and light chains
- Amyloid typing
- Biomarkers (staging and response assessment)
- Stem cell transplant in AL amyloidosis
- Non-transplant chemo-immuno-therapy in AL amyloidosis
- MRD in AL amyloidosis